Probiotic-assisted therapy relieves ulcerative colitis by regulating the intestinal bacteriobi.

. 1.
25 active UC patients were randomly divided into 2 groups, 12 oral probiotics (containing Bacillus cheese Zhang, plant lactobacillus P-8, animal Bifidobacteria milk subseed V9), 13 oral placebo, 2 patients at the same time taking the same dose ofmethalazine, intervention for 12
weeks; The UC Disease Activity Index (UCDAI) was significantly lower in patients in the probiotic group than in the placebo group, and the remission rate increased significantly (91.67% vs. 69.23%); 3.
. Through colonoscopy to obtain the intestinal mucous membrane bacteria, probiotics can inhibit the reduction of bacterial diversity and richness, and increase the number of other beneficial bacteria such as ocyctic
; The relative abundance of beneficial bacteria was significantly negatively related to UDAI.Editor's Recommendation szxZhang Peace Team from Inner Mongolia Agricultural University and Zhou Xiaofeng Team of China-Japan Friendship Hospital published a randomized double-blind placebo-controlled trial results on Microbial Biotechnology in 25 active collapses In patients with selective colitis (UC), it was found that after 12 weeks of treatment with methalazine and probiotics alone, UC symptoms could be more effectively alleviated and the remission rate significantly increased, while increasing the relative abundance of beneficial bacteria in the intestinal mucous membrane bacteriocyst. In addition, there was a significant negative correlation between the relative abundance of beneficial bacteria and the UC disease activity index, suggesting that probiotics could alleviate UC by regulating the gut bacteria.. Microbial Biotechnologymodulation of gut mucosal microbiota as a mechanism of probiotics-base-adjunctive therapy for ulcerative colitisregulates the intestinal mucous membrane bacillus as a probiotic-based aid Mechanisms for treating ulcerative colitis 10.1111/1751-7915.13661 09-23, Article Abstract: This was pilot study aiming to evaluate the. effects of probiotics as adjunctive treatment for ulcerative colitis (UC). Twenty-five active patients with UC were assigned to the probiotic (n s 12) and placebo (n s 13) groups. The probiotic group received mesalazine (60 mg kg-1 day-1) and oral probiotics (containing Lactobacillus casei Zhang, Lactobacillus plantarum P-8 and Bifidobacterium animalis subsp. lactis V9) twice daily for 12 weeks, while the placebo group received the same amounts of people of mesalazine and placebo. The clinical outcomes were assessed. The gut mucosal microbiota was profiled by PacBio single-molecule, real-time(SMRT) sequencing of of the full-length 16S rRNA of biopsy samples obtained by colonoscopy. A largely greater magnitude of reduction was observed in the UC disease activity index (UCDAI) in the probiotic group compared with with the placebo group (P s 0.043), adally by a higher remission rate (91.67% for probiotic-receivers versus 69.23% for placebo-receivers, P s. The probiotics can protect from development of the microbiota diversity and richness. Moreover, the gut mucosal microbiota of the probiotic-receivers hadd greatly more than bacteria like Eubacterium ramulus (P < 0.05), Pediococcus pentosaceus (P < 0.05), Bacoides fragilis (P s 0.02 and) Weissela (P s. 0.04). Additionally, the relative abundances of the reed bacteria correlated but negatively with the UCDAI score, suggesting that the probiotics may alleviate UC symptoms by modulating the gut mucosal microbiota. Our research has provided new insights into the mechanism of the symptomon in UC by applying probiotic-base adjunctive treatment.
First Authors:
. Ping Chen, Haiyan Xu
Corespondence Authors:
Xiao Feng Zhou, Heping Zhang
All Authors:
Ping Chen, Haiyan Xu, Hai Tang, Feiyan Zhao, Chengcong Yang, Lai-Yu Kwok, Chunli Cong, Yan Fang Wu, Wenyi Zhang, Xiao Feng Zhou, He
.